Global Presence
United States
Europe
China
Middle East
What We Do
Molecule IP works with biopharma companies, biotechnology firms and platform technology owners seeking to:
Out-license assets or platforms
In-license assets or platforms
Our work centres on two complementary activities:
Curated introductions
We identify counterparties with genuine strategic and commercial alignment — spanning early- to late-stage opportunities, individual assets and broader technology platforms, without restriction by therapeutic area.
Coordination of exploratory discussions
Following introduction, we manage the practical and relational aspects of early engagement: aligning stakeholders, ensuring appropriate information is exchanged in sequence, and sustaining productive momentum through the initial exploratory phase.
We do not undertake scientific due diligence, formal valuation, or lead commercial negotiation. Our role is to create high-quality connections and to keep early dialogue structured and efficient.
Engagement Model
We employ a flexible hybrid structure that typically combines a modest retainer with success-based components. Where mutual interest and long-term alignment exist, equity participation may be considered.
Each engagement is tailored to the specific opportunity and the parties involved.
Process
Opportunity definition
Detailed understanding of the asset or platform, desired partner profile, and commercial objectives.
Counterparty mapping and approach
Identification of relevant parties followed by carefully framed introductions.
Coordination of early dialogue
Structured management of initial information exchange and meeting cadence.
Transition at mutual interest
Once both parties confirm clear interest, we withdraw so that the principals and their advisors may advance the process independently.
About Molecule IP
Molecule IP was established to raise the quality and efficiency of early-stage partnering in biopharma. We believe durable licensing outcomes begin with well-timed, well-matched introductions and disciplined early dialogue.
Based in Estonia, we work with organisations across the United States, Europe, China and the Middle East.
To explore a potential partnership or licensing opportunity in confidence, please get in touch.
What Our Clients Say
The introductions were well matched and well timed. Rather than a long list of possible counterparties, we were put in front of a small number of parties with a genuine strategic reason to engage, which saved us a considerable amount of time.
Head of Business Development
Clinical-stage biotechnology company, United States
Molecule IP understood the platform properly before approaching anyone. That preparation was evident in the quality of the early conversations and in how quickly discussions moved to substantive questions.
Chief Scientific Officer
Platform technology company, Europe
The coordination of the early dialogue was the most valuable part. Information was exchanged in a sensible sequence and momentum was maintained without either side feeling pressed.
Director of Licensing
Mid-sized pharmaceutical group, Middle East
They withdrew once both parties had confirmed clear interest, exactly as described at the outset. Handing over cleanly to our own team and advisers made the transition into formal negotiation straightforward.
VP, Corporate Development
Biopharmaceutical company, ChinaInsights
14Mar
What partners look for in
an early-stage asset
The questions that shape a licensing conversation long before terms are discussed ...
02Feb
Timing an out-licensing
approach
Why the strongest position is rarely the earliest, and how to judge when to begin ...
21Jan
Bridging expectations between
Western and Asian partners
Practical differences in pace, structure and diligence that shape cross-border deals ...
09Dec
Positioning a technology platform for licensing
Presenting a platform so that its breadth reads as an advantage rather than a lack of focus ...